Efficacy and Safety of Adjuvant Proton Therapy Combined With Surgery for Chondrosarcoma of the Skull Base: A Retrospective, Population-Based Study

Feuvret, L.; Bracci, Stefano; Calugaru, Valentin; Bolle, Stéphanie; Mammar, Hamid; Marzi, Ludovic De; Bresson, D.; Habrand, Jean‐Louis; Mazeron, Jean‐Jacques; Dendale, R.; Noël, Georges

doi:10.1016/j.ijrobp.2015.12.016

Cited by 67 publications

(61 citation statements)

References 25 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aforementioned studies [17][18][19] also showed that the side effects/complications which developed on the skin during proton radiotherapy consisted of mild erythema but this contrasted with our own study observations. Five out of 47 (10.6%) patients had grade 3 side effects which affecting the skin (dermatitis developed in 5 patients) which coexisted with grade 3 side effects affecting the oral/pharynx mucous membrane in 3 patients (i.e.…”

Section: Discussioncontrasting

confidence: 93%

“…the skull base or brain) and consisted of hair loss in 25.6% of cases, fatigue in 10.3% and headaches in 20.5%. In addition, these patients also experienced nausea (12.3%) and middle ear effusion (23.1%), in keeping with other published studies [18,19].…”

Section: Discussionsupporting

confidence: 91%

“…Clinicopathological and therapeutic characteristics of the 47 patient group undergoing proton radiotherapy of all SEs). Indeed, these observations are in line with those reported in other studies [11,[17][18][19]. Combs et al [20] studied proton and other ion therapies given to patients suffering from skull base or brain tumours and found that the most frequent stage SEs included hair loss in 37% of cases, and headaches and fatigue in 27% of cases.…”

Section: Discussionsupporting

confidence: 78%

“…or nausea (8 pts.). Feuwert et al [18] showed that all their patient subjects who had undergone proton radiotherapy on the skull base developed grade 1 or grade 2 early side effects.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

The tolerance of proton radiotherapy — preliminary results

Sas-Korczyńska

Pluta²,

Chrostowska³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 93%

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 78%

“…or nausea (8 pts.). Feuwert et al [18] showed that all their patient subjects who had undergone proton radiotherapy on the skull base developed grade 1 or grade 2 early side effects.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The tolerance of proton radiotherapy — preliminary results

Sas-Korczyńska

Pluta²,

Chrostowska³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

“…The efficacy of proton beam therapy (PBT) for BSs (primarily chordomas and chondrosarcomas [CSs]) of the SB and spine has been reported since the 1980s . Photons emit maximal energy near the body surface; this energy gradually decreases at deeper points in the body.…”

mentioning

confidence: 99%

Proton beam therapy for bone sarcomas of the skull base and spine: A retrospective nationwide multicenter study in Japan

et al. 2017

View full text Add to dashboard Cite

We conducted a retrospective, nationwide multicenter study to evaluate the clinical outcomes of proton beam therapy for bone sarcomas of the skull base and spine in Japan. Eligibility criteria included: (i) histologically proven bone sarcomas of the skull base or spine; (ii) no metastases; (iii) ≥20 years of age; and (iv) no prior treatment with radiotherapy. Of the 103 patients treated between January 2004 and January 2012, we retrospectively analyzed data from 96 patients who were followed‐up for >6 months or had died within 6 months. Seventy‐two patients (75.0%) had chordoma, 20 patients (20.8%) had chondrosarcoma, and four patients (7.2%) had osteosarcoma. The most frequent tumor locations included the skull base in 68 patients (70.8%) and the sacral spine in 13 patients (13.5%). Patients received a median total dose of 70.0 Gy (relative biological effectiveness). The median follow‐up was 52.6 (range, 6.3–131.9) months. The 5‐year overall survival, progression‐free survival, and local control rates were 75.3%, 49.6%, and 71.1%, respectively. Performance status was a significant factor for overall survival and progression‐free survival, whilst sex was a significant factor for local control. Acute Grade 3 and late toxicities of ≥Grade 3 were observed in nine patients (9.4%) each (late Grade 4 toxicities [n = 3 patients; 3.1%]). No treatment‐related deaths occurred. Proton beam therapy is safe and effective for the treatment of bone sarcomas of the skull base and spine in Japan. However, larger prospective studies with a longer follow‐up are warranted.

show abstract